Because of their suppressive abilities on T cells, macrophages and myeloid-derived suppressor cells, as well as regulatory T cells (Tregs) are considered promising therapeutic targets. In order to develop effective immunomodulatory therapeutics for complex diseases, such as cancer or autoimmune disorders, T cell suppression assays are required to assess whether a potential new treatment will inhibit or promote T cell responsiveness upon interaction with key regulatory cells.
In this study by Janss et al., from ImmunXperts, a macrophage suppression assay was used to confirm the efficacy and potency of test compounds on the suppressive capacities of the macrophages on T cells. When comparing secretions of IFNγ and proliferation of CD4 T cells among untreated CD4 T cells alone, untreated CD4 T cells + M1 macrophage and CD4 T cells + M2 macrophages treated with different conditions highlights the suitability of our workflow solutions for a macrophage suppression assay for drug testing.
Thibaut Janss, Juliette Lamy, Sofie Pattijn, and Jana Schockaert
ImmunXperts SA, Rue Auguste Piccard 48, 6041 Gosselies, Belgium
TAMs and the TME: Learn how preclinical in vitro techniques help predict the effect of immunotherapeutics in vivo.
In this example study, the T reg suppression assay was used to assess the suppressive capacity of T regs on T cells upon treatment with three novel test compounds to assess their immunomodulatory potency. The resulting CFSE proliferating cell percentages allowed for a clear understanding on the action of the test compounds.
Seems like you are coming from USA!
Do you want to visit our website in your country?